Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Sarepta Therapeutics, Inc. (SRPT) had Stock-Based Compensation of $53.87M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$401.25M |
|
$-4.89M |
|
$149.38M |
|
$251.87M |
|
$387.96M |
|
$13.29M |
|
$-15.04M |
|
$-1.75M |
|
$-1.75M |
|
$-4.89M |
|
$-4.89M |
|
$-4.89M |
|
$-4.89M |
|
$13.29M |
|
$22.80M |
|
105.43M |
|
105.43M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$2.22B |
|
$325.99M |
|
$964.69M |
|
$3.19B |
|
$502.91M |
|
$847.62M |
|
$1.16B |
|
$1.66B |
|
$1.53B |
|
$1.53B |
|
$1.53B |
|
105.62M |
|
| Cash Flow Statement Financials | |
$-5.61M |
|
$-227.76M |
|
$0.24M |
|
$814.41M |
|
$581.27M |
|
$-233.13M |
|
|
Stock-Based Compensation |
$53.87M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.42 |
|
-- |
|
-- |
|
0.36 |
|
0.55 |
|
62.77% |
|
3.31% |
|
3.31% |
|
-- |
|
-0.44% |
|
-1.22% |
|
$-8.25M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.17 |
|
1.06 |
|
84.52 |
|
-0.32% |
|
-0.32% |
|
-0.15% |
|
-0.21% |
|
$14.46 |
|
$-0.08 |
|
$-0.05 |
|